Nevro (NVRO) Earns Daily Media Impact Rating of 0.11
Media headlines about Nevro (NYSE:NVRO) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nevro earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 46.528172828321 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Nevro Corp (NVRO) Expected to Announce Earnings of -$0.34 Per Share (americanbankingnews.com)
- Nevro Corp (NVRO) Director Sells $804,800.00 in Stock (americanbankingnews.com)
- Nevro Corp (NVRO) Director Sells $1,204,062.24 in Stock (americanbankingnews.com)
- Nevro Corp (NVRO) Shares Sold by Dorsey & Whitney Trust CO LLC (americanbankingnews.com)
- Nevro (NVRO) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
Shares of Nevro (NYSE NVRO) opened at $78.96 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.61 and a quick ratio of 5.91. The firm has a market capitalization of $2,340.00, a price-to-earnings ratio of -63.17 and a beta of -0.51. Nevro has a twelve month low of $65.00 and a twelve month high of $97.70.
Several analysts have weighed in on the company. TheStreet raised Nevro from a “d+” rating to a “c-” rating in a report on Monday, November 6th. ValuEngine lowered Nevro from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. BMO Capital Markets reissued a “buy” rating and issued a $100.00 target price on shares of Nevro in a report on Thursday, December 14th. Northland Securities reissued a “buy” rating and issued a $96.00 target price on shares of Nevro in a report on Tuesday, November 7th. Finally, Leerink Swann reissued an “outperform” rating and issued a $110.00 target price (up previously from $105.00) on shares of Nevro in a report on Tuesday, November 7th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $99.25.
In related news, Director Wilfred E. Jaeger sold 14,458 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $83.28, for a total transaction of $1,204,062.24. Following the sale, the director now owns 1,518 shares of the company’s stock, valued at $126,419.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Wilfred E. Jaeger sold 10,000 shares of the stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $80.48, for a total value of $804,800.00. Following the sale, the director now directly owns 1,518 shares in the company, valued at approximately $122,168.64. The disclosure for this sale can be found here. 12.10% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Nevro (NVRO) Earns Daily Media Impact Rating of 0.11” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/nevro-nvro-earns-daily-media-impact-rating-of-0-11/1903407.html.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.